Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries.
Phillip ScheinbergPublished in: British journal of haematology (2021)
The progress in aplastic anaemia (AA) management is one of success. Once an obscure entity resulting in death in most affected can now be successfully treated with either haematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST). The mechanisms that underly the diminution of haematopoietic stem cells (HSCs) are now better elucidated, and include genetics and immunological alterations. Advances in supportive care with better antimicrobials, safer blood products and iron chelation have greatly impacted AA outcomes. Working somewhat 'mysteriously', anti-thymocyte globulin (ATG) forms the base for both HSCT and IST protocols. Efforts to augment immunosuppression potency have not, unfortunately, led to better outcomes. Stimulating HSCs, an often-sought approach, has not been effective historically. The thrombopoietin receptor agonists (Tpo-RA) have been effective in stimulating early HSCs in AA despite the high endogenous Tpo levels. Dosing, timing and best combinations with Tpo-RAs are being defined to improve HSCs expansion in AA with minimal added toxicity. The more comprehensive access and advances in HSCT and IST protocols are likely to benefit AA patients worldwide. The focus of this review will be on the medical treatment advances in AA.
Keyphrases
- stem cell transplantation
- stem cells
- healthcare
- high dose
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- hematopoietic stem cell
- palliative care
- quality improvement
- ejection fraction
- oxidative stress
- iron deficiency
- mesenchymal stem cells
- metabolic syndrome
- patient reported outcomes
- prognostic factors
- peritoneal dialysis
- pain management
- chronic pain
- insulin resistance
- drug induced
- weight loss
- ankylosing spondylitis
- disease activity
- bone marrow